{
    "clinical_study": {
        "@rank": "40282", 
        "arm_group": {
            "arm_group_label": "HuMax-TF-ADC", 
            "arm_group_type": "Experimental", 
            "description": "All arms of the trial (borh in escalation and expansion phase) will be administered HuMax-TF-ADC"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed\n      population of patients with specified solid tumors"
        }, 
        "brief_title": "HuMax\u00ae-TF-ADC Safety Study in Patients With Solid Tumors", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovary Cancer", 
            "Cervix Cancer", 
            "Endometrium Cancer", 
            "Bladder Cancer", 
            "Prostate Cancer (CRPC)", 
            "Cancer of Head and Neck (SCCHN)", 
            "Esophagus Cancer", 
            "Lung Cancer(NSCLC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Uterine Cervical Neoplasms", 
                "Head and Neck Neoplasms", 
                "Lung Neoplasms", 
                "Ovarian Neoplasms", 
                "Prostatic Neoplasms", 
                "Endometrial Neoplasms", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is conducted in two parts. The dose escalation portion of the trial subjects are\n      enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.\n\n      In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose\n      of HuMax-TF-ADC as determined in Part 1 in three different arms where  at least two of the\n      cancer types will be chosen for the Cohort Expansion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients with relapsed, advanced and/or metastatic cancer who have failed available\n        standard treatments or who are not candidates for standard therapy.\n\n        Patients must have measurable disease\n\n          -  Age \u2265 18 years.\n\n          -  Acceptable renal function\n\n          -  Acceptable liver function\n\n          -  Acceptable hematological status (without hematologic support\n\n          -  Acceptable coagulation status\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          -  Life expectancy of at least three months.\n\n          -  A negative serum pregnancy test (if female and aged between 18-55 years old).\n\n          -  Women who are pregnant or breast feeding are not to be included.\n\n          -  Patients, both females and males, of reproductive potential must agree to use\n             adequate contraception during and for six months after the last infusion of\n             HuMax-TF-ADC.\n\n          -  Following receipt of verbal and written information about the study, patients must\n             provide signed informed consent before any study-related activity is carried out.\n\n        Exclusion Criteria:\n\n          -  Known past or current coagulation defects.\n\n          -  Ongoing major bleeding,\n\n          -  Have clinically significant cardiac disease\n\n          -  A baseline QT interval as corrected by Fridericia's formula (QTcF) > 450 msec, a\n             complete left bundle branch block (defined as a QRS interval \u2265 120 msec in left\n             bundle branch block form) or an incomplete left bundle branch block.\n\n          -  Therapeutic anti-coagulative or long term anti-platelet treatment.\n\n          -  Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage\n             colony stimulating factor support within one week or pegylated G-CSF within two weeks\n             before the Screening Visit.\n\n          -  Have received a cumulative dose of corticosteroid \u2265 100 mg (prednisone or equivalent\n             doses of corticosteroids) within two weeks before the first infusion.\n\n          -  No dietary supplements allowed during the study period, except multivitamins, vitamin\n             D and calcium.\n\n          -  Major surgery within six weeks or open biopsy within 14 days before drug infusion.\n\n          -  Plan for any major surgery during treatment period.\n\n          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain\n             metastases or stroke.\n\n          -  Any anticancer therapy including; small molecules, immunotherapy, chemotherapy\n             monoclonal antibodies or any other experimental drug within four weeks or five half\n             lives, whichever is longest, before first infusion.\n\n          -  Prior treatment with bevacizumab within twelve weeks before the first infusion.\n\n          -  Radiotherapy within 28 days prior to first dose.\n\n          -  Patients who have not recovered from symptomatic side effects of radiotherapy at the\n             time of initiation of screening procedure.\n\n          -  Known past or current malignancy other than inclusion diagnosis, except for:\n\n          -  Cervical carcinoma of Stage 1B or less.\n\n          -  Non-invasive basal cell or squamous cell skin carcinoma.\n\n          -  Non-invasive, superficial bladder cancer.\n\n          -  Prostate cancer with a current PSA level < 0.1 ng/mL.\n\n          -  Any curable cancer with a complete response (CR) of > 5 years duration.\n\n          -  Known human immunodeficiency virus seropositivity.\n\n          -  Positive serology (unless due to vaccination or passive immunization due to Ig\n             therapy) for hepatitis B\n\n          -  Positive serology for hepatitis C based on test at screening.\n\n          -  Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.\n\n          -  Inflammatory lung disease including moderate and severe asthma and chronic\n             obstructive pulmonary disease (COPD) requiring chronic medical therapy.\n\n          -  Ongoing acute or chronic inflammatory skin disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001623", 
            "org_study_id": "GEN701"
        }, 
        "intervention": {
            "arm_group_label": "HuMax-TF-ADC", 
            "intervention_name": "HuMax-TF-ADC", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ovary cancer", 
            "cervix cancer", 
            "endometrium cancer", 
            "bladder cancer", 
            "prostate cancer (CRPC)", 
            "cancer of head and neck (SCCHN)", 
            "esophagus cancer", 
            "lung cancer(NSCLC)"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Ulrik Lassen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "DK-2100"
                    }, 
                    "name": "Rigshospitalet, Copenhagen University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ulrik Lassen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Johann de Bono, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Sueery", 
                        "country": "United Kingdom", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "The Royal Marsden NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Johann de Bono, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (HuMax\u00ae TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor", 
        "overall_contact": {
            "email": "m.schultz@genmab.com", 
            "last_name": "Martin Schultz", 
            "phone": "+4570202728"
        }, 
        "overall_official": {
            "affiliation": "The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust", 
            "last_name": "Johann de Bono, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Health and Medicines Authority", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As this is a phase I trial the main objective is to assess the safety and tolerability of HuMax-TF-ADC throughout the treatment periods of the patients participating in the trial.", 
            "measure": "Adverse events measured throughout the study from first treatment until end of trial.", 
            "safety_issue": "Yes", 
            "time_frame": "After first treatment cycle (3 weeks) and at end of trial (an expected average of 6 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK profile of HuMax-TF-ADC after single and multiple infusions", 
                "safety_issue": "No", 
                "time_frame": "After first treatment cycle (3 weeks) and at end of trial (an expected average of 6 months)"
            }, 
            {
                "description": "Evaluate the anti-tumor activity of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.", 
                "measure": "Anti-tumor activity of HuMax-TF-ADC; tumor size (RECIST), PSA and/or CA-125", 
                "safety_issue": "No", 
                "time_frame": "At end of trial (an expected average of 6 months)"
            }
        ], 
        "source": "Genmab", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genmab", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}